Skip to main content
. 2019 May 31;8(2):e000435. doi: 10.1136/bmjoq-2018-000435

Table 4.

Number of ‘positive’ responses, total number of responses, raw percentage of ‘positive’ responses, cluster (team) adjusted OR and 95% CI for ‘positive’ responses in 2018 vs 2017 and associated p value for the six key questions

Question 2017 Responses 2018 Responses OR 95% CI for OR P value†
n‡ %* n‡ %* Lower Upper
1. Does the MDT have TORs or guidelines to guide the conduct of the meetings? (yes) 20 129 15.5 54 117 46.2 4.8 2.5 9.3 <0.001
2. Are there established criteria for referral of patients to MDT meetings? (yes) 34 129 26.4 62 117 53.0 2.9 2.0 4.4 <0.001
3. Is there a follow-up process to check whether referrals from the MDT are actually made? (yes) 18 129 14.0 22 117 18.8 1.6 0.7 3.5 0.262
4. Does the MDT use clinical practice guidelines/treatment protocols relevant to patients with cancer? (always or usually) 81 129 62.8 72 117 61.5 0.9 0.6 1.3 0.532
5. Does the MDT routinely collect the time from diagnosis to definitive treatment? (yes) 13 128 10.2 22 117 18.8 2.0 0.9 4.1 0.078
6. Are internal audits conducted to confirm that treatment decisions match current best practice? (yes) 9 129 7.0 9 117 7.7 1.2 0.7 1.9 0.543

*Percentage of ‘positive’ responses.

†P value adjusted for team clustering.

‡Number of ‘positive’ responses.

§Total number of responses.

CI, confidence interval; MDT, multidisciplinary team; OR, odds ratio; TOR, Terms of Reference.